{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T02:11:04Z","timestamp":1683511864090},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s00105-006-1185-9","type":"journal-article","created":{"date-parts":[[2006,7,13]],"date-time":"2006-07-13T06:54:59Z","timestamp":1152773699000},"page":"685-689","source":"Crossref","is-referenced-by-count":6,"title":["Calcineurininhibitoren zur topischen Therapie der Psoriasis","Calcineurin inhibitors for topical therapy in psoriasis"],"prefix":"10.1007","volume":"57","author":[{"given":"J.","family":"Wohlrab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1185_CR1","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1468-3083.2004.01054.x","volume":"18","author":"Amichai","year":"2004","unstructured":"Amichai B (2004) Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. J Eur Acad Dermatol Venereol 18: 742\u2013743","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1185_CR2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/archderm.141.9.1152","volume":"141","author":"Bigby","year":"2005","unstructured":"Bigby M (2005) Pimecrolimus and tacrolimus for the treatment of intertriginous and facial psoriasis: are they effective? Arch Dermatol 141: 1152\u20131153","journal-title":"Arch Dermatol"},{"key":"1185_CR3","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1016\/j.bmc.2005.02.049","volume":"13","author":"Billich","year":"2005","unstructured":"Billich A, Vyplel H, Grassberger M et al. (2005) Novel cyclosporin derivates featuring enhanced skin penetration despite increased molecular weight. Bioorg Med Chem 13: 3157\u20133167","journal-title":"Bioorg Med Chem"},{"key":"1185_CR4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0190-9622(08)80012-6","volume":"22","author":"Bousema","year":"1990","unstructured":"Bousema MT, Tank B, Heule F et al. (1990) Placebo-controlled study of psoriasis patients treated topically with a 10% cyclosporine gel. J Am Acad Dermatol 22:126\u2013127","journal-title":"J Am Acad Dermatol"},{"key":"1185_CR5","first-page":"3322","volume":"23","author":"bu-Elmagd","year":"1991","unstructured":"bu-Elmagd K, van TD, Jegasothy BV, Ackerman CD et al. (1991) FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 23: 3322\u20133324","journal-title":"Transplant Proc"},{"key":"1185_CR6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jps.2600840512","volume":"84","author":"Choi","year":"1995","unstructured":"Choi HK, Flynn GL, Amidon GL (1995) Percutaneous absorption and dermal delivery of cyclosporin A. J Pharm Sci 84: 581\u2013583","journal-title":"J Pharm Sci"},{"key":"1185_CR7","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1046\/j.1365-2133.2002.04800.x","volume":"146","author":"Erdogan","year":"2002","unstructured":"Erdogan M, Wright JR Jr, McAlister VC (2002) Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. Br J Dermatol 146: 964\u2013967","journal-title":"Br J Dermatol"},{"key":"1185_CR8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1067\/mjd.2003.169","volume":"48","author":"Freeman","year":"2003","unstructured":"Freeman AK, Linowski GJ, Brady C et al. (2003) Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol 48: 564\u2013568","journal-title":"J Am Acad Dermatol"},{"key":"1185_CR9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1365-2133.2005.06661.x","volume":"152","author":"Gottlieb","year":"2005","unstructured":"Gottlieb AB, Griffiths CE, Ho VC et al. (2005) Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol 152: 1219\u20131227","journal-title":"Br J Dermatol"},{"key":"1185_CR10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.0906-6705.2004.00269.x","volume":"13","author":"Grassberger","year":"2004","unstructured":"Grassberger M, Steinhoff M, Schneider D, Luger TA (2004) Pimecrolimus \u2013 an anti-inflammatory drug targeting the skin. Exp Dermatol 13: 721\u2013730","journal-title":"Exp Dermatol"},{"key":"1185_CR11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2004.06.010","volume":"51","author":"Gribetz","year":"2004","unstructured":"Gribetz C, Ling M, Lebwohl M et al. (2004) Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 51: 731\u2013738","journal-title":"J Am Acad Dermatol"},{"key":"1185_CR12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(87)92829-7","volume":"1","author":"Griffiths","year":"1987","unstructured":"Griffiths CE, Powles AV, Baker BS et al. (1987) Topical cyclosporin and psoriasis. Lancet 1: 806","journal-title":"Lancet"},{"key":"1185_CR13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1468-3083.2003.00692.x","volume":"17","author":"Gupta","year":"2003","unstructured":"Gupta AK, Chow M (2003) Pimecrolimus: a review. J Eur Acad Dermatol Venereol 17: 493\u2013503","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1185_CR14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0022-202X(89)90063-8","volume":"93","author":"Gupta","year":"1989","unstructured":"Gupta AK, Fisher GJ, Elder JT et al. (1989) Topical cyclosporine A inhibits the phorbol ester induced hyperplastic inflammatory response but not protein kinase C activation in mouse epidermis. J Invest Dermatol 93: 379\u2013386","journal-title":"J Invest Dermatol"},{"key":"1185_CR15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000210782","volume":"1","author":"Hermann","year":"1988","unstructured":"Hermann RC, Taylor RS, Ellis CN et al. (1988) Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol 1: 246\u2013249","journal-title":"Skin Pharmacol"},{"key":"1185_CR16","unstructured":"Jahn K (2002) Moderne galenische Zubereitungen zur dermalen Anwendung von Ciclosporin A und Mycophenolatmofetil. Shaker, Aachen"},{"key":"1185_CR17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1468-3083.2005.01122.x","volume":"19","author":"Kroft","year":"2005","unstructured":"Kroft EB, Erceg A, Maimets K et al. (2005) Tacrolimus ointment for the treatment of severe facial plaque psoriasis. J Eur Acad Dermatol Venereol 19: 249\u2013251","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1185_CR18","first-page":"1154","volume":"141","author":"Lebwohl","year":"2005","unstructured":"Lebwohl M, Freeman A, Chapman MS et al. (2005) Proven efficacy of tacrolimus for facial and intertriginous psoriasis. Arch Dermatol 141: 1154","journal-title":"Arch Dermatol"},{"key":"1185_CR19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaad.2004.07.011","volume":"51","author":"Lebwohl","year":"2004","unstructured":"Lebwohl M, Freeman AK, Chapman MS et al. (2004) Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 51: 723\u2013730","journal-title":"J Am Acad Dermatol"},{"key":"1185_CR20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijpharm.2005.12.029","volume":"311","author":"Liu","year":"2006","unstructured":"Liu H, Li S, Wang Y et al. (2006) Effect of vehicles and enhancers on the topical delivery of cyclosporin A. Int J Pharm 311: 182\u2013186","journal-title":"Int J Pharm"},{"key":"1185_CR21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D37C3542MX","volume":"12","author":"Mansouri","year":"2006","unstructured":"Mansouri P, Farshi S (2006) Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J 12: 7","journal-title":"Dermatol Online J"},{"key":"1185_CR22","first-page":"618","volume":"12","author":"Marsland","year":"2002","unstructured":"Marsland AM, Griffiths CE (2002) The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 12: 618\u2013622","journal-title":"Eur J Dermatol"},{"key":"1185_CR23","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1046\/j.1365-2133.1998.02554.x","volume":"139","author":"Mrowietz","year":"1998","unstructured":"Mrowietz U, Graeber M, Brautigam M et al. (1998) The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 139: 992\u2013996","journal-title":"Br J Dermatol"},{"key":"1185_CR24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/00015550310003791","volume":"83","author":"Mrowietz","year":"2003","unstructured":"Mrowietz U, Wustlich S, Hoexter G et al. (2003) An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 83: 351\u2013353","journal-title":"Acta Derm Venereol"},{"key":"1185_CR25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/00015550510039817","volume":"86","author":"Ortonne","year":"2006","unstructured":"Ortonne JP, van de Kerkhof PC, Prinz JC et al. (2006) 0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observer-blinded study. Acta Derm Venereol 86: 29\u201333","journal-title":"Acta Derm Venereol"},{"key":"1185_CR26","unstructured":"Pharmazeutisches Laboratorium des \u201eNeuen Rezeptur-Formularium\u201c (2004) Standardisierte Rezepturen. Govi, Eschborn"},{"key":"1185_CR27","first-page":"141","volume":"31","author":"Rallis","year":"2005","unstructured":"Rallis E, Nasiopoulou A, Kouskoukis C et al. (2005) Successful treatment of genital and facial psoriasis with tacrolimus ointment 0.1%. Drugs Exp Clin Res 31: 141\u2013145","journal-title":"Drugs Exp Clin Res"},{"key":"1185_CR28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1046\/j.1523-1747.2002.00694.x","volume":"119","author":"Rappersberger","year":"2002","unstructured":"Rappersberger K, Komar M, Ebelin ME et al. (2002) Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 119: 876\u2013887","journal-title":"J Invest Dermatol"},{"key":"1185_CR29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D35ZK7V6CS","volume":"10","author":"Scheinfeld","year":"2004","unstructured":"Scheinfeld N (2004) The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review. Dermatol Online J 10: 3","journal-title":"Dermatol Online J"},{"key":"1185_CR30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1990.tb08248.x","volume":"122","author":"Schulze","year":"1990","unstructured":"Schulze HJ, Mahrle G, Steigleder GK (1990) Topical cyclosporin A in psoriasis. Br J Dermatol 122: 113\u2013114","journal-title":"Br J Dermatol"},{"key":"1185_CR31","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaad.2005.05.036","volume":"53","author":"Steele","year":"2005","unstructured":"Steele JA, Choi C, Kwong PC (2005) Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol 53: 713\u2013716","journal-title":"J Am Acad Dermatol"},{"key":"1185_CR32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/archderm.1996.03890280081011","volume":"132","author":"The","year":"1996","unstructured":"The European FK 506 Multicentre Psoriasis Study Group (1996) Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 132: 419\u2013423","journal-title":"Arch Dermatol"},{"key":"1185_CR33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000248005","volume":"180","author":"Tosti","year":"1990","unstructured":"Tosti A, Guerra L, Bardazzi F, Lanzarini M (1990) Topical ciclosporin in nail psoriasis. Dermatologica 180: 110","journal-title":"Dermatologica"},{"key":"1185_CR34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.det.2004.03.013","volume":"22","author":"Wolff","year":"2004","unstructured":"Wolff K (2004) Current concepts and review of pimecrolimus in the treatment of psoriasis. Dermatol Clin 22: 461\u2013465","journal-title":"Dermatol Clin"},{"key":"1185_CR35","first-page":"451","volume":"80","author":"Yamamoto","year":"2000","unstructured":"Yamamoto T, Nishioka K (2000) Topical tacrolimus is effective for facial lesions of psoriasis. Acta Derm Venereol 80: 451","journal-title":"Acta Derm Venereol"},{"key":"1185_CR36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0889-857X(05)70266-0","volume":"22","author":"Yocum","year":"1996","unstructured":"Yocum DE (1996) Cyclosporine, FK-506, rapamycin, and other immunomodulators. Rheum Dis Clin North Am 22: 133\u2013154","journal-title":"Rheum Dis Clin North Am"},{"key":"1185_CR37","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archderm.134.9.1101","volume":"134","author":"Zonneveld","year":"1998","unstructured":"Zonneveld IM, Rubins A, Jablonska S et al. (1998) Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 134: 1101\u20131102","journal-title":"Arch Dermatol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1185-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-006-1185-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1185-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T01:37:29Z","timestamp":1683509849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-006-1185-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1007\/s00105-006-1185-9","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}